Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives

• Main Authors: Davidson M, Starling N
• Format: Article
• Language: English
• Published: Dove Medical Press 2016-11-01
• Series: OncoTargets and Therapy
• Subjects: HER2; trastuzumab; gastric cancer; immunohistochemistry; in-situ hybridisation
• Online Access: https://www.dovepress.com/trastuzumab-in-the-management-of-gastroesophageal-cancer-patient-selec-peer-reviewed-article-OTT

Michael Davidson, Naureen Starling Department of Gastrointestinal Oncology, The Royal Marsden Hospital NHS Foundation Trust, London, UK Abstract: The addition of trastuzumab to the treatment of a subset of patients with advanced gastric and gastroesophageal junction cancers showing HER2 positivity has been shown to confer clinical benefit; however, questions remain over the optimal methods for defining and selecting such patients. This review provides an overview of current standards for assessing HER2 positivity, the evolving treatment landscape for HER2-positive gastric and esophageal cancers and the challenges and potential future directions in optimal patient selection for HER2-targeted therapy. Keywords: HER2, trastuzumab, gastric cancer, immunohistochemistry, in situ hybridization